SHANGHAI, China, March 9, 2026, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies announce that, pursuant to the Notice of Adjustment of the List of Securities for Southbound Trading under the Shanghai Connect on March 6, 2026 and the Announcement on Adjustment of the List of Eligible Securities for Southbound Trading under the Shenzhen Connect on March 6, 2026, the shares of the company issued and listed on The Stock Exchange of Hong Kong Limited (the “Shares”) have been included in the list of eligible shares for Southbound Trading of the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs (collectively, the “Stock Connect”) with effect from March 9, 2026.
?
The inclusion reflects market recognition of the development potential of the company’s core CAR-T business, operational compliance and share liquidity, and is in line with the long-term development strategy of the company and the fundamental interests of all shareholders. Following the inclusion of the Shares into Stock Connect, eligible mainland Chinese investors may directly invest in the Shares through the Stock Connect trading systems of the Shanghai Stock Exchange and the Shenzhen Stock Exchange. This is expected to provide mainland investors with a more convenient investment channel, significantly enhance market attention and liquidity, and inject strong impetus into the company’s capital market development.
?
About CARsgen Therapeutics Holdings Limited
CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen’s mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable.
?
Forward-looking Statements
All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group’s current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group’s control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading “Principal Risks and Uncertainties” in our most recent annual report and interim report and other announcements and reports made available on our corporate website, . No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release.
?
Contact CARsgen
For more information, please visit /
Public Relations: PR@carsgen.com
Investor Relations: IR@carsgen.com